P21 vs PE-22-28
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: P021, Ac-DGGLAG-NH2
A synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.
Also: PE22-28, Spadin Analog
A synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | P21 | PE-22-28 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | P21 acts as a CNTF small-molecule peptide mimetic. It enhances neurogenesis in the hippocampus, reduces tau phosphorylation, inhibits neuroinflammation, and improves synaptic plasticity. Designed to be orally bioavailable. | PE-22-28 selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore domain potassium channel highly expressed in the brain. TREK-1 inhibition increases neuronal excitability and enhances serotonergic and noradrenergic neurotransmission. This mechanism is distinct from traditional SSRIs and produces rapid-onset antidepressant effects in preclinical studies. |
| Common Dosing | Limited community data available See research protocols | 100-300 mcg intranasal or subcutaneous Once daily |
| Administration | Oral (nasal in some studies) | Intranasal or subcutaneous injection |
| Typical Duration | Ongoing supplementation in studies | Research protocols vary, often 2-4 weeks |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show cognitive improvement in Alzheimer's mouse models. Research demonstrates increased neurogenesis, reduced tau pathology, and improved learning/memory. Being developed for Alzheimer's and age-related cognitive decline. | Animal studies demonstrate significant antidepressant and anxiolytic effects within days of administration (faster than traditional SSRIs which take weeks). PE-22-28 shows improved stability compared to full Spadin while maintaining efficacy. Research indicates potential for treatment-resistant depression. No human clinical trials conducted yet. |
Frequently Asked Questions: P21 vs PE-22-28
What is the difference between P21 and PE-22-28?
P21 is a cognitive peptide that a synthetic peptide mimetic of cntf (ciliary neurotrophic factor) designed for neurodegenerative disease. promotes neurogenesis and reduces neuroinflammation. PE-22-28 is a cognitive peptide that a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring antidepressant peptide. pe-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of spadin. works by blocking trek-1 potassium channels in the brain. The main differences lie in their mechanisms of action and clinical applications.
Which is better, P21 or PE-22-28?
Neither is universally "better" - the choice depends on your specific goals. P21 is typically used for cognitive purposes, while PE-22-28 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can P21 and PE-22-28 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using P21 and PE-22-28 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.